|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||72.70 - 73.55|
|52 Week Range||62.88 - 86.39|
|PE Ratio (TTM)||24.69|
|Earnings Date||Oct 31, 2018|
|Forward Dividend & Yield||3.03 (4.18%)|
|1y Target Est||79.80|
Elon Musk shocked investors last week when he tweeted he was considering taking Tesla private at $420 a share and that funding was secured. Earlier this year, Roseanne Barr blamed Ambien for her sending a tweet comparing former Obama aide Valerie Jarrett to an ape. Tesla TSLA CEO Elon Musk told The New York Times he sometimes takes Ambien because it's "often a choice of no sleep or Ambien." But some concerned board members have noted that the drug contributes to Musk's late-night tweeting, the outlet reported, citing a person familiar with the board's thinking.
GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.
As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...
In the second quarter, GlaxoSmithKline’s (GSK) revenue was nearly flat YoY (year-over-year) at 7.3 billion British pounds, reflecting 4% growth at constant exchange rates offset by a 4% impact by foreign exchange. The pound strengthened, weakening GSK’s revenue. The chart below shows GlaxoSmithKline’s revenue since the first quarter of 2017.
Reporting EN This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for ...
Novo Nordisk (NVO) reported net revenues of 54.3 billion Danish kroner in the first half of 2018 compared to 57.1 billion Danish kroner in H1 2017. That’s a ~5% YoY (year-over-year) decline.
Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States. Galafold - approved on Friday by U.S. regulators - is the first new Fabry disease treatment in the country in over 15 years, and will compete with Sanofi SA's infused Fabrazyme, which has an average U.S. list price of $340,000 for adults, according to Amicus. Galafold is an oral therapy for Fabry disease, a sometimes fatal genetic condition in which accumulation of fat damages several organs.
U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs. Galafold, known chemically as migalastat, will be the first new Fabry treatment on the U.S. market in over 15 years, and will compete with Sanofi SA’s infused Fabrazyme. An estimated 3,000 people in the United States are diagnosed with the disease.
A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.
Alnylam Pharmaceuticals’ (ALNY) interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
New U.S. sanctions against Iran took effect on Tuesday and President Donald Trump, who defied Washington's allies to impose them, pledged that companies doing business with Tehran would be barred from ...
German car and truck manufacturer Daimler has dropped plans to expand its Iran business. "We have ceased our already restricted activities in Iran in accordance with the applicable sanctions", Daimler said. In early 2016, Daimler established a joint venture with vehicle manufacturer and dealer Iran Khodro Co to make and distribute Mercedes-Benz trucks in the country.
On August 2, Regeneron Pharmaceuticals (REGN) posted earnings results for its fiscal second quarter of 2018, which ended on June 30. It posted strong results and raised its fiscal 2018 guidance. It registered strong sales and earnings while achieving significant product pipeline milestones.
Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.
It’s another busy day for European corporate news, with forecast-beating numbers from Air France-KLM, BNP Paribas and Lloyds Banking the highlights of a fresh batch of company earnings.
Regeneron Pharmaceuticals on Thursday reported adjusted income of $5.45 per share on $1.61 billion in sales for the second quarter.
PARIS/ZURICH/LONDON (Reuters) - Sanofi and Novartis said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal. At the same time the European Medicines Agency, which oversees drug safety across the bloc, warned of bigger than expected staff losses and cuts in some activities as a result of having to move from London to Amsterdam due to Brexit. Europe's equivalent of the U.S. Food and Drug Administration now expects to lose around 30 percent of its workforce as it prepares to relocate by March 2019.
PARIS/ZURICH/LONDON (Reuters) - Sanofi (SASY.PA) and Novartis (NOVN.S) said on Wednesday they planned to increase stockpiles of medicines in Britain in preparation for potential disruption if the UK crashes out of the European Union without a deal. At the same time the European Medicines Agency, which oversees drug safety across the bloc, warned of bigger than expected staff losses and cuts in some activities as a result of having to move from London to Amsterdam due to Brexit. Europe's equivalent of the U.S. Food and Drug Administration now expects to lose around 30 percent of its workforce as it prepares to relocate by March 2019.
LONDON (AP) — Pharmaceutical company Sanofi has begun to stockpile more drugs in Britain than usual as part of contingency plans for delays in deliveries after Britain leaves the European Union.
SA has been making drug-shortage contingency plans for more than a year to prepare for the U.K. failing to reach a deal with the European Union on Brexit, according to a person familiar with the matter. The move is the latest sign large European companies are worried about the prospects of a hard Brexit, where the U.K. doesn’t reach a deal over its future relationship with the European Union, despite repeated attempts at reassurance from British government officials.